The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma
Masayuki Hagiwara, Atsushi Fushimi, Kazuhiro Matsumoto, Mototsugu Oya
Topics & Concepts
MedicineNivolumabHazard ratioOncologyClear cell renal cell carcinomaInternal medicineRenal cell carcinomaPARP1BiomarkerImmunotherapyCancerPoly ADP ribose polymeraseConfidence intervalBiologyBiochemistryGenePolymeraseRenal cell carcinoma treatmentPARP inhibition in cancer therapyCancer Immunotherapy and Biomarkers